When does Solasia report earnings and how could that move 4597.T stock?

Solasia’s earnings are due 13 Feb 2026. The report will move 4597.T stock through guidance, R&D updates and sales detail. Positive clinical timelines or stronger sales could lift the share price; setbacks could trigger a sharp decline.

What are the main valuation concerns for 4597.T stock?

Valuation concerns include a high P/S of **25.10**, negative EPS **-8.96**, and negative free cash flow per share **-2.60**. These point to reliance on pipeline success for upside in 4597.T stock.

What price levels should traders watch for 4597.T stock after earnings?

Traders should watch support near **JPY 25.00** and resistance around **JPY 35.00–40.00**. Expect increased volatility and volume; manage position size and use stop limits for 4597.T stock.

How does Meyka AI view Solasia stock in its grading and forecast?

Meyka AI rates 4597.T with a score out of 100 at **67.59 (B — HOLD)** and Meyka AI's forecast model projects **JPY 26.70** in one year. Grades and forecasts are model outputs and not investment guarantees for 4597.T stock.

JP Stocks

After Hours: Solasia Pharma (4597.T JPX) before Feb 2026 earnings: key catalysts

ByDanny Kontos February 12, 2026February 12, 2026

Solasia Pharma K.K. (4597.T stock) trades at JPY 30.00 in after-hours trade on 12 Feb 2026 as the market positions ahead of an earnings release due 13 Feb 2026. Investors are parsing pipeline milestones and product sales for signs of cash runway and revenue momentum. Key near-term drivers are Darinaparsin (SP-02) phase III readouts and the progress of Arfolitixorin (SP-05) in phase III. Volume today was 30,833,000 shares versus a 50-day average of 39,577,230, signalling focused attention ahead of the report.